Breaking Finance News

Zacks Investment Research downgraded Hill-Rom Holdings, Inc. (NYSE:HRC) to Hold in a statement released earlier today.

Having a price of $76.66, Hill-Rom Holdings, Inc. (NYSE:HRC) traded -0.53% lower on the day. With the last stock price close down 4.18% from the two hundred day average, compared with the S&P 500 Index which has increased 0.02% over the date range. Hill-Rom Holdings, Inc. has recorded a 50-day average of $76.89 and a two hundred day average of $76.82. Volume of trade was down over the average, with 214,539 shares of HRC changing hands under the typical 510,703

Zacks Investment Research has downgraded Hill-Rom Holdings, Inc. (NYSE:HRC) to Hold in a statement released on 05/25/2017.

Recent Performance Chart

Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. has 52 week low of $50.50 and a 52 week high of $84.65 with a P/E ratio of 46.64 and has a market capitalization of $0.

General Company Details For Hill-Rom Holdings, Inc. (NYSE:HRC)

Hill-Rom Holdings, Inc. is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company's products and services include Patient Support Systems, Front Line Care and Surgical Solutions. The Company sells and rents its specialty frames and surfaces, and mobility solutions, as well as its clinical workflow solutions, in the United States and Canada through its North America Patient Support Systems segment, and in regions outside of the United States and Canada through its International Patient Support Systems segment. Its Front Line Care segment globally sells and rents respiratory care products, and sells medical diagnostic equipment and a diversified portfolio of devices that assess, diagnose, treat and manage a range of illnesses and diseases. Under its Surgical Solutions segment, the Company sells its surgical products globally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *